Meeting
2020 ASCO Virtual Scientific Program
A phase Ib study of abemaciclib in combination with pembrolizumab for patients (pts) with stage IV Kirsten rat sarcoma mutant (KRAS-mut) or squamous non-small cell lung cancer (NSCLC) (NCT02779751): Interim results.
Authors
Jean-Louis Pujol
Centre Hospitalier Universitaire, Maladies Respiratoires, Montpellier, France
Jean-Louis Pujol , Johan F. Vansteenkiste , Luis G. Paz-Ares , Vanesa Gregorc , Julien Mazieres , Mark M. Awad , Pasi A. Janne , Michael Jon Chisamore , Anwar Hossain , Yanyun Chen , Joseph Thaddeus Beck
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02779751
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9562)
DOI
10.1200/JCO.2020.38.15_suppl.9562
Abstract #
9562
Poster Bd #
328
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab.
First Author: Sara M. Tolaney
Poster
2022 ASCO Annual Meeting
Three-year outcomes and correlative analyses in patients with non–small cell lung cancer (NSCLC) and a very high PD-L1 tumor proportion score (TPS) ≥ 90% treated with first-line pembrolizumab.
First Author: Biagio Ricciuti
Poster
2023 ASCO Annual Meeting
Real-world outcomes of first-line immune checkpoint inhibitors with or without chemotherapy in KRAS G12C altered NSCLC according to PD-L1 status.
First Author: Charu Aggarwal
Poster
2023 ASCO Annual Meeting
ARC-10: A phase 3 study to evaluate zimberelimab + domvanalimab versus pembrolizumab in front-line, PD-L1-high, locally advanced or metastatic non–small-cell lung cancer.
First Author: Christos Chouaid